A novel scalable electrode array and system for non-invasively assessing gastric function using flexible electronics

Armen A. Gharibans1,2,3 | Tommy C. L. Hayes1 | Daniel A. Carson1 | Stefan Calder2 | Chris Varghese1 | Peng Du2,3 | Yaara Yarmut2 | Stephen Waite2 | Celia Keane1,2 | Jonathan S. T. Woodhead2,4 | Christopher N. Andrews2,5 | Greg O’Grady1,2

1Department of Surgery, University of Auckland, Auckland, New Zealand
2Alimetry Ltd, Auckland, New Zealand
3Auckland Bioengineering Institute, University of Auckland, Auckland, New Zealand
4Maurice Wilkins Centre for Molecular Biodiscovery, The University of Auckland, Auckland, New Zealand
5Department of Medicine, University of Calgary, NB Calgary, Alberta, Canada

Correspondence
Greg O’Grady, Department of Surgery, University of Auckland, Auckland, New Zealand.
Email: greg.ogrady@auckland.ac.nz

Funding information
This work was supported by the New Zealand Health Research Council and the Royal Australasian College of Surgeons’ John Mitchell Crouch Fellowship.

Abstract

Background: Disorders of gastric function are highly prevalent, but diagnosis often remains symptom-based and inconclusive. Body surface gastric mapping is an emerging diagnostic solution, but current approaches lack scalability and are cumbersome and clinically impractical. We present a novel scalable system for non-invasively mapping gastric electrophysiology in high-resolution (HR) at the body surface.

Methods: The system comprises a custom-designed stretchable high-resolution “peel-and-stick” sensor array (8 × 8 pre-gelled Ag/AgCl electrodes at 2 cm spacing; area 225 cm²), wearable data logger with custom electronics incorporating bioamplifier chips, accelerometer and Bluetooth synchronized in real-time to an App with cloud connectivity. Automated algorithms filter and extract HR biomarkers including propagation (phase) mapping. The system was tested in a cohort of 24 healthy subjects to define reliability and characterize features of normal gastric activity (30 min fasting, standardized meal, and 4 h postprandial).

Key Results: Gastric mapping was successfully achieved non-invasively in all cases (16 male; 8 female; aged 20–73 years; BMI 24.2 ± 3.5). In all subjects, gastric electrophysiology and meal responses were successfully captured and quantified non-invasively (mean frequency 2.9 ± 0.3 cycles per minute; peak amplitude at mean 60 min postprandially with return to baseline in <4 h). Spatiotemporal mapping showed regular and consistent wave activity of mean direction 182.7° ± 73 (74.7% antegrade, 7.8% retrograde, 17.5% indeterminate).

Conclusions and Inferences: BSGM is a new diagnostic tool for assessing gastric function that is scalable and ready for clinical applications, offering several biomarkers that are improved or new to gastroenterology practice.

KEYWORDS
bioelectronics, diagnostics, functional gastrointestinal disorders, gastric motility

This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.
© 2022 The Authors. Neurogastroenterology & Motility published by John Wiley & Sons Ltd.
1 | INTRODUCTION

Chronic gastric symptoms affect up to 10% of adults, are increasing in prevalence, and impart a vast quality of life and cost burden.\(^1,2,3,4\) These symptoms encompass early satiation, excessive postprandial fullness, epigastic pain and burning, nausea and vomiting, and are clinically recognized in functional dyspepsia, chronic nausea and vomiting syndromes, and gastroparesis.\(^5\) However, accurately defining, differentiating and subtyping these overlapping conditions remains an important problem in gastroenterology, owing to a lack of objective diagnostic tests. The only widely available test of gastric function is measurement of gastric emptying, which is used to define gastroparesis, but is controversial due to its limited specificity, weak correlation with symptoms, and inconsistency over time.\(^6,7\) There is a need for new tests of gastric function, and an ideal test would offer actionable biomarkers while being safe, non-invasive, scalable and accessible, and cost-efficient.\(^7\)

A century ago, Walter C. Alvarez introduced electrogastrography (EGG) as a non-invasive diagnostic tool for gastric function.\(^8\) EGG measures the bioelectrical slow waves that coordinate gastric motility, and also registers gastric contractile activity through an increase in signal power.\(^9,10\) A substantial literature has been generated to show that EGG abnormalities are consistently prevalent in patients with gastric symptoms,\(^11-13\) yet EGG did not achieve common clinical adoption. Limitations to EGG include its focus on frequency as the predominant measure of abnormality, sensitivity to noise that could lead to misinterpretation of data, and an inability to account for a wide variability in gastric anatomical position.\(^14,15\)

Recently, body surface gastric mapping (BSGM or high-resolution EGG) has been proposed as a novel diagnostic method to overcome the limitations of EGG, by employing a dense grid of electrodes to measure and map gastric activity in high-resolution at the epigastrium.\(^14,16,17\) The convergence of an improved physiological understanding of gastric slow wave patterns in health vs disease states,\(^18\) modern amplifiers,\(^19\) and filters that more robustly discriminate gastric activity from noise,\(^20,21\) have revitalized interest in the clinical potential of gastric electrophysiology.\(^14\) Recent studies have shown that BSGM can identify novel biomarkers such as slow wave direction or pattern that may offer superior symptom correlations compared to traditional EGG and gastric emptying testing.\(^16,17\)

Until now, the use of BSGM has been restricted to research applications. This is because the test has been impractical, involving the time-consuming placement of many individual electrodes and managing the associated cable bundle, which is also a cleaning and disinfection barrier to clinical use. In addition, BSGM has required highly expensive specialized acquisition systems restricted to investigational use, and complex analysis approaches requiring substantial signal processing expertise. In this work, we developed a novel non-invasive clinical solution for BSGM that overcomes these problems through the application of flexible electronics and miniaturized wearable circuitry, together with advances in automated data processing and visualization. The novel BSGM system and method was subjected to bench-top verification followed by an experimental evaluation in healthy volunteers to demonstrate its reliability in generating improved or new clinical biomarkers of human gastric function, including robust frequency and power spectra, the direction and pattern of wave travel, and meal response metrics.

2 | MATERIALS AND METHODS

2.1 | System overview

The novel BSGM system was designed to accommodate a clinical testing framework comprising a 30min fasting baseline, consumption of a standardized meal, and up to 4h of postprandial testing (Figure 1). This timeframe was chosen to reflect the typical period of the gastric meal response.\(^22\) The BSGM system (overviewed in Figure 2) is comprised of a flexible and conformable pre-gelled "peel-and-stick" high-resolution (HR) sensor array, an ambulatory data logger with custom electronics specifically tuned for gastric bioelectrical data, and a native iOS App with HIPAA-compliant cloud connectivity and Bluetooth 5.0 synchronization to the data logger. The App guides the user through test setup, including user-specific algorithm guided array positioning, requests symptom data from the subject during testing according to a validated design, and manages data transfers. Automated algorithms were also developed for filtering and extracting and visualizing clinical biomarkers. Each of these components are discussed in further detail below.

2.1.1 | Sensor array

Gastric bioelectrical signals are of weak amplitude and signal strength diminishes exponentially as distance from the source...
increases, meaning that electrodes should be positioned directly over the stomach for capturing reliable data. An electrode sensor array was, therefore, designed to a size that was capable of achieving a position consistently overlying the stomach with high reliability when placed on the epigastrium (196 cm²; data based on a separate proprietary anatomical study). The sensor array (Figures 2A and 3A) was screen-printed in layers on a 21 × 16 cm thermoplastic polyurethane (TPU) substrate. TPU was chosen for its ease of manufacturing, biocompatibility and high conformability, allowing comfortable adherence to the user’s epigastrium (Figure 3B), including through a full range of movement without delaminating from the skin.

An 8 × 8 grid of electrodes (11 mm diameter, 20 mm center-to-center electrode spacing) with adjacent reference and ground electrodes was screen-printed onto the TPU substrate using Ag/AgCl ink. Each electrode pad has an associated conductive track coalescing to a "mating panel" (Figure 2B). An insulating dielectric layer was then applied to coat the entire surface except for the electrode pads and mating panel (indicated by blue areas in Figure 2B). A conversion process was then undertaken (Figure 3A). First, an adhesive laminate was applied over the dielectric layer. Conductive hydrogel discs were then positioned on each Ag/AgCl electrode to ensure low-impedance charge transfer at the skin interface. Finally, the adhesive and hydrogel layers were covered by a backing layer, which is peeled off immediately prior to application. The entire sensor array was mass-fabricated with an automated process involving roll-to-roll screen-printing, die-cutting, and converting machinery, before individual packaging in moisture barrier foil pouches (Alimetry Ltd, New Zealand).

A total of 22 completed arrays underwent comprehensive testing to ensure adequate electrode quality and performance according to the ANSI/AAMI EC12:2000 Standard and a further 30 arrays underwent shelf life testing. Further details regarding the array testing procedure can be found in the Supplementary Methods.

### 2.1.2 | Connector

A compact board-to-board connector design was introduced that overcomes a key design challenge in the field of high-resolution wearable electronics, being the attachment of a flexible array to a rigid circuit without the need for bulky connector attachments or cables. The sensor array interfaces with the data logger device by means of a custom flexible printed circuit cable and high density compression connector with a 0.2 mm thick PI stiffener on the back of the connector end, placed between a machined stainless-steel clamp (Alimetry Ltd) (Figure 2C). The other end of the cable attaches to a zero-insertion-force connector on a custom mating PCB that allows repeatable connections to the data logger without additional tools.

### 2.1.3 | Data logger

An ambulatory data logger (Figure 2A) was designed and fabricated, employing all custom electronics and firmware, and housed within an off-the-shelf casing (Hammond Manufacturing, USA; 147 × 89 × 25 mm). Bioelectrical signals are recorded at 250 Hz, amplified and digitized by low-noise programmable gain amplifiers with each input compared against a common reference electrode as shown on Figure 2A, to provide unipolar recordings for 64 channels. Data is stored on removable internal storage until uploaded to a HIPAA-compliant cloud server via the App. An onboard accelerometer is used to record motion during the recording. Bluetooth connection with the App is maintained throughout the recording session, and to facilitate data upload. After a successful upload, data is securely deleted from the data logger in preparation for the subsequent test. After assembly, the data logger electronics underwent comprehensive electrical performance testing to ensure design criteria were met, as well as electromagnetic compatibility (EMC) testing. Further details regarding these testing methods are provided in the Supplementary Methods.
2.1.4 | App and array placement algorithm

The companion App was programmed in Swift v.5.1, being designed for use on an iPad mini (Apple, CA, USA). A password-protected administration section allows the user to register the test and participant details, customize recording variables, and to guide setup. As noted above, reliable placement of the electrode array directly over the stomach location is an essential design requirement for reliable data capture in body surface gastric mapping. The App, therefore, further incorporated an array positioning algorithm taking into account guided measurements between xiphoid and umbilicus, xiphoid and anterior superior iliac spine (ASIS), and abdominal circumference (Figure 2Di).26 These measurements were used to calculate a patient-specific array location with reference to the umbilicus, which is displayed to the user. Guided placement of the array by this algorithm, in conjunction with the chosen array size, aimed to reliably capture the gastric field within the recording electrode in the high majority of participants, by accounting for known anatomical variations.
(verified in a previous proprietary anatomical study). The App also undertakes an impedance check of the array prior to test initiation to ensure optimal data quality (Figure 2Dii).

2.2 | Clinical and analytical methods

Ethical approval for the clinical studies was obtained from the Auckland Health Research Ethics Committee (AHREC, reference AH1130). This study focused on clinical evaluation of the novel system in 24 healthy subjects to demonstrate reliability for outputting each of the stated gastric biomarkers. Healthy subjects were 18 years or older with no known active GI symptoms or pathology, not meeting Rome IV criteria for a functional GI disorder, and not taking any medication known to affect gastrointestinal motility including anxiolytics and antidepressants. Additional exclusion criteria were any of the following: metabolic, neurogenic or endocrine disorder known to cause gastric dysmotility (including scleroderma, multiple sclerosis and hyperthyroidism), active GI infection, inflammatory bowel disease, previous gastric or esophageal surgery, history of GI malignancy, open abdominal wounds or abdominal skin not intact, fragile skin, allergy to adhesives and pregnancy. Additionally, those with body mass index (BMI) >35 were excluded, as data reliability is currently uncertain above this threshold.

2.2.1 | Experimental protocol

Subjects were fasted for at least 8 h and were asked to not use nicotine or consume caffeine in the morning of their study. Measures of chronic gut symptoms were evaluated by the validated Patient Assessment of Gastrointestinal Disorders Symptom Severity Index (PAGI-SYM) and Patient Assessment of Upper Gastrointestinal Disorders-Quality of Life (PAGI-QOL) questionnaires. The anterior abdomen was shaved if required and the skin prepped using a conductive gel (NuPrep; Weaver and Company, CO, USA). The novel flexible sensor array was then placed on the epigastrium, guided by the positioning algorithm. As per Figure 1, gastric activity was measured over a 30 min fasted period, followed by consumption of a standardized meal over 10 min, including a 232 kcal nutrient drink (230ml Ensure; Abbott Nutrition, IL, USA) and an oatmeal energy bar (250 kcal with 5 g fat, 45 g carbohydrate, 10 g protein, 7 g fiber; Clif Bar & Company, CA, USA), and a further 4 h postprandial recording. Subjects remained reclined at 45 degrees for the entirety of the recording duration with their legs elevated in a comfortable position, and were instructed to limit movement and talking, avoid sleeping, and refrain from touching the array. At the end of the test, any adverse events were recorded and subjects were given a short questionnaire regarding system usability. Comfort during the test and any discomfort on removal of the array were assessed using electronic 100-point visual analogue scales (0 "very uncomfortable" to 100 "very comfortable" for the test; and 0 "not painful" to 100 "most painful imaginable" for the array removal).

2.2.2 | Signal processing and analysis

Data collected using the BSGM device were processed using an automated proprietary algorithm that enabled filtering, biomarker outputs, and visualizations. In brief, each of the 64 channels were analyzed to first remove segments of significant artifact based on the methods of Gharibans et al. Further steps in the algorithm then generated the biomarkers of gastric function. Spatial heat maps were generated to show the predicted gastric location within the mapped field according to a power spectrum. Spectral analyses were performed using a composite of channels located centrally over the gastric position in the heat map, by a short-time Fourier transform (4 minute windows with 75% overlap), visualized as frequency-amplitude and amplitude-time plots. Dominant frequency (cycles per minute; cpm), mean amplitude (μV), and variance in the dominant frequency were calculated for each participant and as summary statistics for the whole cohort. Meal response was characterized by the increase in the power of the spectral analysis after a meal (power ratio), and was calculated separately for the first 2 h postprandially (PR2h) and the entire postprandial period (PR4h). Average dominant frequency was calculated for the PR2h phase, when signal power is high. The duration taken to return to a stable baseline was also calculated in each period with reference to the fasting period. The frequency-amplitude spectrograms were also averaged, after normalizing amplitude for each participant, to define overall trends in the meal response power curve across the cohort. Mean amplitude was correlated against BMI.

Spatiotemporal metrics were derived for each subject using methods similar to those described by Gharibans et al. Wave patterns were visualized as propagation animations, and their directionality was defined by manual classification. This was performed by five independent reviewers with conflicts resolved by consensus panel. Each reviewer visually assessed the animated data in 15 min epochs and classified these as antegrade, retrograde, indeterminate, or low-amplitude noise, with the latter being excluded from subsequent percentage calculations. Summary data on wave directions were also computed via the algorithm and displayed as polar histograms.

2.2.3 | Statistical analysis

Normality was assessed by visual inspection of Q-Q plots. Continuous independent normal variables were compared using Student’s t-test, and continuous independent non-normal variables using the Mann–Whitney U test. More than two sets of continuous dependent normal variables were compared using the repeated measures ANOVA, with a Bonferroni post-test correction applied. More than two sets of continuous dependent
non-normal variables were compared using Friedman’s test, with a Dunn correction for multiple comparisons applied. Strength of association between variables was determined using Pearson’s rank correlation coefficient (r). Sample size calculations for Array testing can be found in the Supplementary Methods. The statistical significance threshold was $p < 0.05$. All statistical analysis was performed using GraphPad Prism v.8 (GraphPad Software, CA, USA) and R version 4.0.3 (R Foundation for Statistical Computing, Vienna, Austria). Values are reported as the mean ± standard deviation (SD) unless stated otherwise.

3 | RESULTS

3.1 | Flexible array and data logger testing

The mass-fabricated flexible arrays were tested to ensure the maximum Euclidean distance between ink layers was at most 1 mm, each hydrogel pad was only in contact with a singular Ag/AgCl electrode and that no adhesive layer overlapped with hydrogel pads. Based on testing of 22 arrays as determined by the a priori sample size calculation, all distances between Ag/AgCl and Ag layers for all electrodes were <1 mm; all distances between Ag/AgCl and dielectric layers for all electrodes were <1 mm; each hydrogel pad was in contact with exactly 1 Ag/AgCl electrode for all the electrodes on the arrays and the adhesive layer did not overlap the hydrogel layer on any electrodes.

The array electrical testing met ANSI/AAMI EC12:2000 ECG Electrode Standards as detailed in Supplementary Results, together with the electrical performance testing of the data logger.

3.2 | Clinical evaluation

Twenty-four healthy subjects (16 male; 8 female) participated, of median age 28.5 (range 20–73 years). The mean BMI was $24.2 \pm 3.5$ kg/m² (range 17.9–31.2), with 15 subjects of BMI < 25, and 9 of BMI ≥ 25). These healthy control subjects reported a minimal GI symptom burden (mean PAGI-SYM $0.17 \pm 0.33$; mean GCSI $0.21 \pm 0.40$) and a high GI-related quality of life (mean total PAGI-QOL $4.84 \pm 0.26$).

3.3 | Stomach localization, impedance and artifact

The sensor array positioning algorithm captured the area of high signal power from the stomach accurately in all 24 subjects. In 22/24 (92%) participants this area was located centrally within the mapped field, vs nearer to the edge of the mapped field in the remaining 2/24 (8%) (Figure 4A). The average heat map from all 24 recordings is shown in Figure 4B, confirming an overall average central position. The mean impedance was $84.1$ kΩ (SEM $10.8$ kΩ) (Figure 4C). The high majority of data were usable for analysis following automated removal of contamination by artifacts and subsequent signal recovery (mean $94.8 \pm 4.8\%$).

FIGURE 4  (A) Spatial heat maps for three participants, demonstrating the estimated signal power in the gastric range over the recording duration. Each electrode is represented by a gray circle, and the subject’s left (L) and right (R) are indicated. Approximate stomach location can be inferred by the region of greatest amplitude (yellow). (B) Average heat map for all 24 participants. (C) Box and whisker plot of mean impedance for all 24 subjects
3.4 | Frequency, amplitude, and meal response

Clear dominant frequency bands were identified in all patients (e.g., Figure 5A,B). Mean dominant frequency was 2.9 cpm ± SD 0.3 (range 2.4–3.4 cpm), which was stable within participants (mean intra-subject variability ± 0.43 cpm, range 0.10–0.83). Mean amplitude over the 4.5 h test duration ranged from 17.1 to 65.3 μV across the cohort (mean 35.2 ± SEM 2.7). The mean fasted amplitude was 24.2 ± SEM 2.2 μV, which was stable within participants (mean intra-subject variability ± 0.43 μV, range 0.10–0.83). Mean amplitude significantly increased during the 0–2 h postprandial period (mean 39.1 μV ± SEM 3.2; p < 0.001 vs fasted period) and during the 2–4 h postprandial period was mean 34.3 μV ± SEM 3.2 (p = 0.0001 vs fasted period) (Figure 6A). Power ratios were: PR_{2h} 1.75 ± SD 0.90 and PR_{4h} 1.61 ± SD 0.73. Amplitude was negatively correlated with BMI (r = -0.41; p = 0.046; Figure 6B).

Three examples of meal responses are shown with frequency-amplitude spectrograms in Figure 5A. These cases demonstrate the variability present in the time to maximum postprandial amplitude, which could occur nearly immediately after the meal (e.g., Figure 5AIi), or following a lag phase (e.g., Figure 5Aii). Figure 5A also demonstrates the variability in the length of the meal response (i.e., duration before return to baseline). The postprandial amplitude returned to baseline by 4 h postmeal in 21/24 subjects; the remaining subjects either did not show a substantial increase in power above baseline (n = 2; PR_{2h} 1.03 and 1.23), or amplitude did not return to baseline prior to the end of the test (n = 1; PR_{2h} 1.21 vs PR_{3-4h} 2.72). The average frequency-amplitude plot for all subjects is presented in Figure 5B. This data shows that, on-average, amplitude steadily increased and peaked within 2 h after the meal, before gradually returning towards baseline fasted values by the end of the test.

3.5 | Wave propagation profiling

Spatiotemporal wave propagation profiling was performed in all 24 subjects. Example data are shown in Figure, with Figure 7A,I and Figure 7B,ii showing examples of typical antegrade propagation (see also Supplementary Animations). On classification, 74.7% of all subjects recordings were antegrade. 7.8% retrograde, and 17.5% were indeterminate due to apparent looping of the body surface dipole that precluded clear determination of direction. An example of retrograde activity is shown in Figure 7B,i. Retrograde waves were observed in 10/24 subjects, typically during the first 1.5 h postprandially, lasting median 22.5 min, and being sustained for >15 min in 7 subjects. Mean wave direction in the first 2 h postprandially was 182.7° ± 37 (Figure 7C). The average distribution of wave direction across all subjects is shown in the phase map in Figure 7D, demonstrating dominant antegrade propagation.

3.6 | Safety

No participants had significant adverse events. One participant reported low-grade itchiness related to the sensor array (resolution within 30 min), and another had moderate erythema of the epigastrium upon removal. Discomfort on removal of the sensor array was low for most subjects (mean 26.5 ± 22.2/100), while comfort during the test was high (mean 69.9 ± 27.1/100).
DISCUSSION

In this study we present a novel scalable flexible high-resolution electrode array and complete clinical system for body surface gastric mapping (BSGM). First human data confirm that a dense field of gastric signal data was effectively captured in all subjects, enabling several biomarkers of gastric activity to be accurately characterized, including frequency and power spectra, meal response characteristics, and spatiotemporal metrics of wave propagation. These data demonstrate that the new system is a reliable non-invasive tool for characterizing gastric electrophysiology at high-resolution, offering a translational platform that is now ready for clinical applications. The test was well tolerated by all subjects, with no significant adverse events.

The BSGM system is shown to overcome several of the key technical limitations of EGG. First, the combination of the large array size and a patient-specific positioning system meant that the region of highest gastric signal power could be routinely and reliably captured within the mapped field. This is essential because amplitude falls exponentially as electrodes move off the stomach’s location, which is highly variable. Moreover, summing multiple signals from the region of highest gastric power substantially improves the accuracy of spectral analysis, reducing false positive data. Second, defining gastric propagation patterns is a valuable advance over EGG, because gastric dysrhythmias are now recognized as being spatially complex, with abnormal propagation patterns now known to occur at normal frequencies. Third, the novel system integrates multiple technical improvements that together enhance signal-to-noise discrimination, which was a further key pitfall with EGG interpretation. These improvements included modern high-fidelity bioamplifiers embedded in custom hardware and firmware specifically tuned to gastric parameters, and a conformable electrode array achieving low impedance at the skin interface.

The solution introduced here also represents many advances over previous BSGM systems used in research applications. Gharbians et al and Somarajan et al. employed 5 × 5 grids of individually placed cardiac electrodes, while Bradshaw et al. employed a 4 × 4 grid. All of these systems required individual electrodes and cables, being cumbersome for clinical use and involving long setup times, as well as being difficult to reliably clean to hospital standards in an era of increasing concern regarding patient cross-contamination. Individual electrode systems are also subject to inconsistent spacing and higher risk of cross-talk. Our flexible and conformable mass-fabricated electrode array overcomes these issues while obviating the need for prior imaging of the stomach’s location due to its large
size combined with an individualized positioning algorithm. The electrode density is much greater than previous approaches (including those employing flexible electronics), enabled by the introduction of a screen-printed solution, careful optimization of track routing, and a novel interposed clamp connector. This connector efficiently overcomes the problems of mating a stretchable array with a rigid circuit board and could, therefore, find utility in other fields of body surface electronics including cardiac, neural and skeletal muscle applications. Finally, the system also remains portable and user-friendly, including an App to guide rapid standardized setup.

The presented system is fully scalable with arrays already being mass-fabricated under ISO13485 standards, and is ready for clinical application. This is timely, because the objective assessment of gastric function is an area of current clinical concern. Gastric emptying measurement has recently fallen under renewed scrutiny after a prominent study reported that it did not adequately classify patients and was inconsistent over time. Gastric emptying correlates with symptoms when optimally performed, albeit weakly, but its role in guiding diagnosis and management remains controversial. Meanwhile, traditional forms of electrogastrography (EGG) are not currently recommended for clinical use, partly due to the limitations described above, while other tests such as antroduodenal manometry and fundal accommodation testing generally remain restricted to niche applications and/or specialist centers.

New tests are needed that reference underlying pathophysiological mechanisms and provide actionable biomarkers in order to progress from symptom-based diagnosis, diagnosis by exclusion, and trial-and-error therapy. BSGM appears promising because it includes several biomarkers that hold promise independently or cumulatively, and which correlate with symptoms in emerging datasets, while being non-invasive and accessible in any outpatient setting.

The next step will be to apply the BSGM system in large cohorts of patients and controls to robustly assess clinical utility. The current data provides an indication of normal ranges for BSGM biomarkers, but it would be valuable to expand these to reference ranges, and then to evaluate whether these differ by demographics and with alternative meals. It was notable that a small proportion of gastric activity in our healthy subjects propagated in a retrograde direction after a prominent study reported that it did not adequately classify patients and was inconsistent over time. Gastric emptying correlates with symptoms when optimally performed, albeit weakly, but its role in guiding diagnosis and management remains controversial.

Meanwhile, traditional forms of electrogastrography (EGG) are not currently recommended for clinical use, partly due to the limitations described above, while other tests such as antroduodenal manometry and fundal accommodation testing generally remain restricted to niche applications and/or specialist centers. New tests are needed that reference underlying pathophysiological mechanisms and provide actionable biomarkers in order to progress from symptom-based diagnosis, diagnosis by exclusion, and trial-and-error therapy. BSGM appears promising because it includes several biomarkers that hold promise independently or cumulatively, and which correlate with symptoms in emerging datasets, while being non-invasive and accessible in any outpatient setting.

Signal processing and analysis methods remain in ongoing development. A recent technical paper has validated the accuracy of BSGM in measuring the propagation direction of individual wavefronts at the body surface with direct reference to simultaneous high-resolution serosal mapping, using similar techniques to those applied here.

This study provides confidence that the technique is reliable, while also paving the way for future studies that provide more granular data on individual wave direction throughout entire recordings. This step will also enable temporal correlations between symptom onset and retrograde wave patterns, in order to further elucidate the emerging clinical significance of retrograde gastric propagation. Further work to introduce and validate artifact identification schemes would be valuable. In addition, modeling and bench-top studies also suggest that it may be possible in future to identify more complex wave patterns that occur in the stomachs of patients (e.g., colliding wavefronts, conduction blocks and re-entrant activity), although this has not yet been validated experimentally. An additional limitation is that this study was performed in healthy subjects of normal weight, and the reliability of the system requires further validation in obese subjects. Previously, Gharihans et al have shown the ability to measure BSGM data up to a BMI of at least 35, which was, therefore, applied as the cut-off here.

In summary, our novel flexible electrode array and BSGM system provides a robust clinical solution for non-invasively profiling gastric electrophysiology at the body surface. The system is scalable, validated, and ready for clinical applications, offering several biomarkers that are improved or new to gastroenterology practice.

**AUTHOR CONTRIBUTIONS**

AG, GOG, and SC designed the device and research. AG, TH, DAC, SC, JW, and CK performed the studies. AG, TH, DAC, SC, CV, PD, SW, and JW analyzed the data. AG, YY, CA, and GOG provided supervision. AG, GOG, CV, TH, DAC, CA, SC, and YY wrote the paper and approved the final version for publication.
ACKNOWLEDGMENTS
Open access publishing facilitated by The University of Auckland, as part of the Wiley - The University of Auckland agreement via the Council of Australian University Librarians.

CONFLICT OF INTEREST
AG, PD, CNA, and GO hold grants and intellectual property in the field of GI electrophysiology and are members of University of Auckland spin-out companies: The Insides Company (GO), FlexiMap (PD), and Alimetry (AG, SC, YY, JSTW, PD, CNA and GO). DAC, TCLH, and CV have no relevant conflicts to declare.

PREVIOUS PRESENTATIONS
This work was presented at Digestive Diseases Week 2021: Gharibans, A., et al. (2021). “A NEW BODY SURFACE GASTRIC MAPPING: A NOVEL NON-INVASIVE WEARABLE DIAGNOSTIC DEVICE FOR MEASUREMENT OF GASTRIC FUNCTION USING STRETCHABLE ELECTRONICS.” Gastroenterology 160(6): S-95-S-96.

ORCID
Daniel A. Carson https://orcid.org/0000-0002-5089-2807
Chris Varghese https://orcid.org/0000-0001-7369-8639
Peng Du https://orcid.org/0000-0002-6913-7545
Greg O’Grady https://orcid.org/0000-0002-5998-1080

REFERENCES
1. Aziz I, Palsson OS, Törnblom H, Sperber AD, Whitehead WE, Simrén M. Epidemiology, clinical characteristics, and associations for symptom-based Rome IV functional dyspepsia in adults in the USA, Canada, and the UK: a cross-sectional population-based study. Lancet Gastroenerol Hepatol. 2018;3(4):252-262.
2. Aziz I, Palsson OS, Whitehead WE, Sperber AD, Simrén M, Törnblom H. Epidemiology, clinical characteristics, and associations for Rome IV functional nausea and vomiting disorders in adults. Clin Gastroenterol Hepatol. 2019;17(5):878-886.
3. Lacy BE, Weiser KT, Kennedy AT, Crowell MD, Talley NJ. Functional dyspepsia: the economic impact to patients. Aliment Pharmacol Ther. 2013;38(2):170-177.
4. Andreasson A, Talley NJ, Walker MM, et al. An increasing incidence of upper gastrointestinal disorders over 23 years: a prospective population-based study in Sweden. Am J Gastroenterol. 2021;116(1):210-213. doi:10.14309/ajg.0000000000000972
5. Stanghellini V, Chan FKL, Hasler WL, et al. Gastroduodenal disorders. Gastroenterology, 2016;150(6):1380-1392.
6. Pasricha PJ, Grover M, Yates KP, et al. Functional dyspepsia and gastroparesis in tertiary care are interchangeable syndromes with common clinical and pathologic features. Gastroenterology. 2021;160(6):2006-2017.
7. Camilleri M, Chedid V. Actionable biomarkers: the key to resolving disorders of gastrointestinal function. Gut. 2020;69(10):1730-1737.
8. THE ELECTROGASTROGRAM AND WHAT IT SHOWS. JAMA. 1922;78(15):1116. doi:10.1001/jama.1922.02640680200008
9. Smout AJ, van der Schee EJ, Grashuis JL. What is measured in electrogastrography? Dig Dis Sci. 1980;25(3):179-187.
10. Zhu H, Chen JDZ. Gastric distension alters frequency and regularity but not amplitude of the gastric slow wave. Neurogastroenterol Motil. 2004;16(6):745-752. doi:10.1111/j.1365-2982.2004.00571.x
11. Bhat S, Varghese C, Carson DA, et al. Gastric dysrhythmia in gastroesophageal reflux disease: a systematic review and meta-analysis. Esophagus. 2021;18:425-435. doi:10.1007/s10338-021-00820-6
12. Carson DA, Bhat S, Hayes TCL, et al. Abnormalities on electrogastrography in nausea and vomiting syndromes: a systematic review, meta-analysis, and comparison to other gastric disorders. Dig Dis Sci. 2021;67:773-785. doi:10.1007/s10620-021-07026-x
13. Varghese C, Carson DA, Bhat S, et al. Clinical associations of functional dyspepsia with gastric dysrhythmia on electrogastrography: a comprehensive systematic review and meta-analysis. Neurogastroenterol Motil. 2021;33:e14151.
14. Carson DA, O’Grady G, Du P, Gharibans AA, Andrews CN. Body surface mapping of the stomach: new directions for clinically evaluating gastric electrical activity. Neurogastroenterol Motil. 2021;33:e14048.
15. Verhagen MA, Van Schelven LJ, Samsom M, Smout AJ. Pitfalls in the analysis of electrogastrographic recordings. Gastroenterology. 1999;117(2):453-460.
16. Gharibans AA, Coleman TP, Mousa H, Kunkel DC. Spatial patterns from high-resolution electrogastrography correlate with severity of symptoms in patients with functional dyspepsia and gastroparesis. Clin Gastroenterol Hepatol. 2019;17(13):2668-2677.
17. Somarajan S, Muszynski ND, Olson JD, et al. The effect of chronic nausea on gastric slow wave spatiotemporal dynamics in children. Neurogastroenterol Motil. 2020;33:e14035.
18. O’Grady G, Angell TR, Du P, et al. Abnormal initiation and conduction of slow-wave activity in gastroparesis, defined by high-resolution electrical mapping. Gastroenterology. 2012;143(3):589-598.e3.
19. Erickson JC, Hayes JA, Bustamante M, et al. Intsy: a low-cost, open-source, wireless multi-channel bioamplifier system. Physiol Meas. 2019;39(3):035008.
20. Gharibans AA, Kim S, Kunkel D, Coleman TP. High-resolution electrogastrogram: a novel, noninvasive method for determining gastric slow-wave direction and speed. IEEE Trans Biomed Eng. 2017;64(4):807-815.
21. Gharibans AA, Smarr BL, Kunkel DC, Kriegsfield LJ, Mousa HM, Coleman TP. Artifact rejection methodology enables continuous, noninvasive measurement of gastric myoelectric activity in ambulatory subjects. Sci Rep. 2018;8(1):5019.
22. Abell TL, Camilleri M, Donohoe K, et al. Consensus recommendations for gastric emptying scintigraphy: a joint report of the American gastroenterology and motility society and the society of nuclear medicine. J Nucl Med Technol. 2008;36(1):44-54.
23. O’Grady G, Angell TR, Paskaranandavadiel N, et al. Methods for high-resolution electrical mapping in the gastrointestinal tract. IEEE Rev Biomed Eng. 2019;12:287-302.
24. Gharibans AA, Coleman T, Mousa H, Kunkel D. High-density multi-channel electrode Array improves the accuracy of cutaneous electrogastrography across subjects with wide-ranging BMI: 1235. Am J Gastroenterol. 2018;113:5708.
25. McAdams E. Bioelectrodes. In: Webster JG, ed. Encyclopedia of Medical Devices and Instrumentation. John Wiley & Sons, Inc; 2006:120-166. doi:10.1002/0471728776.emd013
26. Ruenruaysab K, Calder S, Hayes T, O’Grady G, Gharibans A, Du P. Effects of anatomical variations on body surface gastric mapping. Conf Proc IEEE Eng Med Biol Soc. 2020;2020:2388-2391.
27. Rentz AM, Kahrilas P, Stanghellini V, et al. Development and psychometric evaluation of the patient assessment of upper gastrointestinal symptom severity index (PAGI-SYM) in patients with upper gastrointestinal disorders. Qual Life Res. 2004;13(10):1737-1749.
28. De la loge C, Trudeau E, Marquis P, et al. Cross-cultural development and validation of a patient self-administered questionnaire to assess quality of life in upper gastrointestinal disorders: the PAGI-QOL®. Qual Life Res. 2004;13(10):1751-1762.
29. Koch KL, Stern RM. Handbook of Electrogastrography. Oxford University Press; 2004.
30. Yin J, Chen JDZ. Electrogastrography: methodology, validation and applications. J Neurogastroenterol Motil. 2013;19(1):5-17. doi:10.5056/jnm.2013.19.1.5

31. Du P, O’Grady G, Cheng LK, Pullan AJ. A multiscale model of the electrophysiological basis of the human electrogastrogram. Biophys J. 2010;99(9):2784-2792. doi:10.1016/j.bpj.2010.08.067

32. Bortolotti M. Electrogastrography: a seductive promise, only partially kept. Am J Gastroenterol. 1998;93(10):1791-1794.

33. Calder S, O’Grady G, Cheng LK, Du P. A simulated anatomically accurate investigation into the effects of biodiversity on electrogastrography. IEEE Trans Biomed Eng. 2020;67(3):868-875. doi:10.1109/tbme.2019.2922449

34. Angeli TR, Cheng LK, Du P, et al. Loss of interstitial cells of Cajal and patterns of gastric dysrhythmia in patients with chronic unexplained nausea and vomiting. Gastroenterology. 2015;149(1):56-66.e5.

35. Bradshaw LA, Cheng LK, Chung E, et al. Diabetic gastroparesis alters the biomagnetic signature of the gastric slow wave. Neurogastroenterol Motil. 2016;28(6):837-848.

36. Kurniawan JF, Tjhia B, Wu VM, et al. An adhesive-integrated stretchable silver-silver chloride electrode Array for unobtrusive monitoring of gastric neuromuscular activity. Adv Mater Technol. 2021;6(5):2001229. doi:10.1002/admt.202001229

37. Vijayvargiya P, Jameie-Oskooei S, Camilleri M, Chedid V, Erwin PJ, Murad MH. Association between delayed gastric emptying and upper gastrointestinal symptoms: a systematic review and meta-analysis. Gut. 2019;68(5):804-813.

38. Tack J, Schol J, Horowitz M. Gastroparesis: a dead-end street after all? Gastroenterology. 2021;160(6):804-813.

39. Lacy BE, Crowell MD, Cangemi DJ, Lunsford TN, Simren M, Tack J. Diagnostic evaluation of gastric motor and sensory disorders. Off J Am College Gastroenterol. 2021;116(12):2345.

40. Patcharatrakul T, Gonlachanvit S. Technique of functional and motility test: how to perform antroduodenal manometry. J Neurogastroenterol Motil. 2013;19(3):395-404.

41. Camilleri M. Testing the sensitivity hypothesis in practice: tools and methods, assumptions and pitfalls. Gut. 2002;51(Suppl 1):i34-i40.

42. O’Grady G, Du P, Cheng LK, et al. Origin and propagation of human gastric slow-wave activity defined by high-resolution mapping. Am J Physiol Gastrointest Liver Physiol. 2010;299(3):G585-G592.

43. Berry R, Miyagawa T, Paskaranandavadivel N, et al. Functional physiology of the human terminal antrum defined by high-resolution electrical mapping and computational modeling. Am J Physiol Gastrointest Liver Physiol. 2016;311(5):G895-G902.

44. Chan CHA, Aghabaie Z, Paskaranandavadivel N, Avci R, Cheng LK, Angeli-Gordon TR. Localized gastric distension disruptions slow-wave entrainment leading to temporary ectopic propagation: a high-resolution electrical mapping study. Am J Physiol Gastrointest Liver Physiol. 2021;321(6):G656-G667.

45. O’Grady G, Gharibans AA, Du P, Huizinga JD. The gastric conduction system in health and disease: a translational review. Am J Physiol Gastrointest Liver Physiol. 2021;321(5):G527-G542.

46. Bhat S, Varghese C, Carson DA, et al. Electrogastrography abnormalities in pediatric gastroduodenal disorders: a systematic review and meta-analysis. J Pediatr Gastroenterol Nutr. 2021;73:9-16. doi:10.1097/MPG.0000000000003140

47. Berry R, Cheng LK, Du P, et al. Patterns of abnormal gastric Pacemaking after sleeve gastrectomy defined by laparoscopic high-resolution electrical mapping. Obes Surg. 2017;27(8):1929-1937.

48. THH W, Angeli TR, Beban G, et al. Slow-wave coupling across a gastroduodenal anastomosis as a mechanism for postsurgical gastric dysfunction: evidence for a “gastrointestinal aberrant pathway.”. Am J Physiol Gastrointest Liver Physiol. 2019;317(2):G141-G146.

49. Tack J, Corsetti M, Camilleri M, et al. Plausibility criteria for putative pathophysiological mechanisms in functional gastrointestinal disorders: a consensus of experts. Gut. 2018;67(8):1425-1433.

50. Hunt JN, Smith JL, Jiang CL. Effect of meal volume and energy density on the gastric emptying of carbohydrates. Gastroenterology. 1985;99(6):1326-1330.

51. Calder S, Cheng LK, Andrews C. Validation of non-invasive body-surface gastric mapping for detecting electrophysiological biomarkers by simultaneous high-resolution serosal mapping in a porcine. bioRxiv. 2021. Accessed January 5, 2022. https://www.biorexiv.org/content/10.1101/2021.08.01.454685.abstract

52. O’Grady G, Gharibans A, Carlson S, Andrews C. Retrograde slow-wave activation: a missing link in gastric dysfunction? Neurogastroenterol Motil. 2021;33(4):e14112.

53. Calder S, O’Grady G, Cheng LK, Peng D. A theoretical analysis of electrogastrography (EGG) signatures associated with gastric dysrhythmias. IEEE Trans Biomed Eng. 2017;64(7):1592-1601.

SUPPORTING INFORMATION
Additional supporting information may be found in the online version of the article at the publisher’s website.